<--- Back to Details
First PageDocument Content
Immunosuppressants / Monoclonal antibodies / Autoimmune diseases / Rheumatology / Adalimumab / Ankylosing spondylitis / C-reactive protein / Inflammation / Spondyloarthropathy / Medicine / Health / Arthritis
Immunosuppressants
Monoclonal antibodies
Autoimmune diseases
Rheumatology
Adalimumab
Ankylosing spondylitis
C-reactive protein
Inflammation
Spondyloarthropathy
Medicine
Health
Arthritis

FOOD AND DRUG ADMINISTRATION

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 17,07 KB

Share Document on Facebook

Similar Documents

KULLANMA TALİMATI HUMIRA PEN (Adalimumab 40 mg/0.8 ml) kullanıma hazır enjeksiyon kalemi Derialtına enjeksiyon yoluyla uygulanır. • •

DocID: 1vrYV - View Document

アプリケーションノート No.20 カイコを用いた各種 FCGR の調製とヒト IgG との相互作用解析 【Syringe】240μM FCGR2A 【Cell】27.5μM adalimumab 【Buffer】PBS (pH7.4),

DocID: 1uEy8 - View Document

Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Rabattverträge* zu HUMIRA® (Adalimumab) Wirtschaftliche Verordnung von HUMIRA® (Adalimumab) von AbbVie durch Rabattverträge zwischen AbbVie und folgenden Krankenkassen: actimonda Krankenkasse BKK Gildemeister Seiden

DocID: 1r9Jj - View Document

Business / Economy / Pharmaceutical sciences / Pharmaceuticals policy / Pharmacy / Pharmaceutical industry / CAC 40 / Sanofi / Novartis / Hikma Pharmaceuticals / Teva Pharmaceutical Industries / Adalimumab

December 4, 2015 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum 1. Teva, Takeda Form Generics Joint Venture in Japan Teva Pharmaceu

DocID: 1qVa0 - View Document